BRIEF published on 11/19/2025 at 23:05, 4 months 11 days ago Les résultats financiers de Medicure pour le troisième trimestre 2025 reflètent une croissance du chiffre d'affaires malgré une perte nette. Marley Drug Croissance Des Revenus Perte Nette Ventes D'AGGRASTAT® Résultats Financiers De Mediure
BRIEF published on 11/19/2025 at 23:05, 4 months 11 days ago Medicure's Q3 2025 Financial Results Reflect Revenue Growth Despite Net Loss Revenue Growth Marley Drug Net Loss AGGRASTAT® Sales Medicure Financial Results
PRESS RELEASE published on 11/19/2025 at 23:00, 4 months 11 days ago Medicure Reports Financial Results for Quarter Ended September 30, 2025 Medicure Inc. reports Q3 2025 results with total net revenue of $8.2 million, an overview of financial performance and key highlights Financial Performance Medicure Inc. Net Revenue Q3 2025 Results Highlights
BRIEF published on 11/13/2025 at 23:35, 4 months 17 days ago Medicure annoncera ses résultats financiers du troisième trimestre 2025 le 20 novembre Résultats Financiers Medicure Inc. Conférence Téléphonique Produits Pharmaceutiques Américains AGGRASTAT® Et ZYPITAMAG®
BRIEF published on 11/13/2025 at 23:35, 4 months 17 days ago Medicure to Announce Q3 2025 Financial Results on November 20 Financial Results Conference Call Medicure Inc. U.S. Pharmaceuticals AGGRASTAT® And ZYPITAMAG®
PRESS RELEASE published on 11/13/2025 at 23:30, 4 months 17 days ago Medicure To Present Financial Results on November 20, 2025 Call at 8:30 AM ET for Quarter Ended September 30, 2025 Medicure Inc. will present Financial Results for Q3 2025 on November 20, 2025, focusing on pharmaceutical development and commercialization in the U.S. market Financial Results Conference Call Pharmaceuticals Medicure Inc. Healthcare Products
BRIEF published on 08/20/2025 at 23:35, 7 months 11 days ago Medicure publie ses résultats financiers du deuxième trimestre 2025 Résultats Financiers Perte Nette Revenu Net Investissement Dans La Recherche Entreprise Pharmaceutique
BRIEF published on 08/20/2025 at 23:35, 7 months 11 days ago Medicure Reports Q2 2025 Financial Results Financial Results Net Loss Net Revenue Research Investment Pharmaceutical Business
PRESS RELEASE published on 08/20/2025 at 23:30, 7 months 11 days ago Medicure Reports Financial Results for Quarter Ended June 30, 2025 Medicure Inc. reports Q2 2025 financial results, including increased revenue from Marley Drug and ZYPITAMAG(R), and enhanced adjusted EBITDA. Find full details at www.medicure.com Financial Results Medicure Inc. Marley Drug ZYPITAMAG Q2 2025
BRIEF published on 08/18/2025 at 23:35, 7 months 13 days ago Medicure to Announce Q2 2025 Financial Results via Conference Call Financial Results Conference Call Pharmaceuticals Medicure Q2 2025
Published on 04/01/2026 at 13:30, 12 minutes ago Electric Metals (USA) Limited Announces OTCQB Ticker Symbol Change to EMUS and Grants Deferred Share Units to Directors
Published on 04/01/2026 at 13:30, 12 minutes ago First Helium CEO Update Highlights Strategic Positioning of Oil and Helium Assets Amid Global Supply Uncertainty
Published on 04/01/2026 at 13:16, 26 minutes ago Early Warning Press Release - Titanium Completes Arrangement to be Taken Private
Published on 04/01/2026 at 13:35, 7 minutes ago DeFi Technologies Appoints Jacob Lindberg as Chief Revenue Officer of Valour, Its Asset Management Business, to Lead Nordic and European Expansion
Published on 04/01/2026 at 13:29, 12 minutes ago mVISE AG successfully extends its 22/26 convertible bond until 2030
Published on 04/01/2026 at 13:29, 13 minutes ago Turkiye Garanti Bankasi A.S.: CMB Approval for Bond Issuance to Foreign Markets
Published on 04/01/2026 at 13:23, 19 minutes ago Turkiye Garanti Bankasi A.S.: Brokerage Houses Warrants Redemption Prices
Published on 04/01/2026 at 13:18, 24 minutes ago Turkiye Garanti Bankasi A.S.: About the Dividend Distribution of 2025
Published on 04/01/2026 at 08:00, 5 hours 42 minutes ago Transfert du contrat de liquidité aupres de Natixis Oddo BHF
Published on 04/01/2026 at 08:00, 5 hours 42 minutes ago Résultats annuels 2025 - ANR par action en hausse de + 8,1 % à 97,10 € - Fonds propres consolidés : 740 M€
Published on 03/31/2026 at 20:08, 17 hours 34 minutes ago SMTPC - Communiqué sur les résultats annuels 2025
Published on 03/31/2026 at 19:05, 18 hours 36 minutes ago SFPI GROUP: implementation of a new liquidity contract
Published on 03/31/2026 at 19:05, 18 hours 36 minutes ago Groupe SFPI : mise en oeuvre d'un nouveau contrat de liquidité
